Cargando…
VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages
Immune evasion of SARS-CoV-2 undermines current strategies tocounteract the pandemic, with the efficacy of therapeutic virus-neutralizing monoclonal antibodies (nAbs) being affected the most. In this work, we asked whether two previously identified human cross-neutralizing nAbs, iB14 (class VH1-58)...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224930/ https://www.ncbi.nlm.nih.gov/pubmed/35743680 http://dx.doi.org/10.3390/jpm12060895 |
_version_ | 1784733491677626368 |
---|---|
author | Kulemzin, Sergey V. Sergeeva, Maria V. Baranov, Konstantin O. Gorchakov, Andrey A. Guselnikov, Sergey V. Belovezhets, Tatyana N. Volkova, Olga Yu. Najakshin, Alexander M. Chikaev, Nikolai A. Danilenko, Daria M. Taranin, Alexander V. |
author_facet | Kulemzin, Sergey V. Sergeeva, Maria V. Baranov, Konstantin O. Gorchakov, Andrey A. Guselnikov, Sergey V. Belovezhets, Tatyana N. Volkova, Olga Yu. Najakshin, Alexander M. Chikaev, Nikolai A. Danilenko, Daria M. Taranin, Alexander V. |
author_sort | Kulemzin, Sergey V. |
collection | PubMed |
description | Immune evasion of SARS-CoV-2 undermines current strategies tocounteract the pandemic, with the efficacy of therapeutic virus-neutralizing monoclonal antibodies (nAbs) being affected the most. In this work, we asked whether two previously identified human cross-neutralizing nAbs, iB14 (class VH1-58) and iB20 (class VH3-53/66), are capable of neutralizing the recently emerged Omicron (BA.1) variant. Both nAbs were found to bind the Omicron RBD with a nanomolar affinity, yet they displayed contrasting functional features. When tested against Omicron, the neutralizing activity of iB14 was reduced 50-fold, whereas iB20 displayed a surprising increase in activity. Thus, iB20 is a unique representative of the VH3-53/66-class of nAbs in terms of breadth of neutralization, which establishes it as a candidate for COVID-19 therapy and prophylactics. |
format | Online Article Text |
id | pubmed-9224930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92249302022-06-24 VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages Kulemzin, Sergey V. Sergeeva, Maria V. Baranov, Konstantin O. Gorchakov, Andrey A. Guselnikov, Sergey V. Belovezhets, Tatyana N. Volkova, Olga Yu. Najakshin, Alexander M. Chikaev, Nikolai A. Danilenko, Daria M. Taranin, Alexander V. J Pers Med Article Immune evasion of SARS-CoV-2 undermines current strategies tocounteract the pandemic, with the efficacy of therapeutic virus-neutralizing monoclonal antibodies (nAbs) being affected the most. In this work, we asked whether two previously identified human cross-neutralizing nAbs, iB14 (class VH1-58) and iB20 (class VH3-53/66), are capable of neutralizing the recently emerged Omicron (BA.1) variant. Both nAbs were found to bind the Omicron RBD with a nanomolar affinity, yet they displayed contrasting functional features. When tested against Omicron, the neutralizing activity of iB14 was reduced 50-fold, whereas iB20 displayed a surprising increase in activity. Thus, iB20 is a unique representative of the VH3-53/66-class of nAbs in terms of breadth of neutralization, which establishes it as a candidate for COVID-19 therapy and prophylactics. MDPI 2022-05-29 /pmc/articles/PMC9224930/ /pubmed/35743680 http://dx.doi.org/10.3390/jpm12060895 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kulemzin, Sergey V. Sergeeva, Maria V. Baranov, Konstantin O. Gorchakov, Andrey A. Guselnikov, Sergey V. Belovezhets, Tatyana N. Volkova, Olga Yu. Najakshin, Alexander M. Chikaev, Nikolai A. Danilenko, Daria M. Taranin, Alexander V. VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages |
title | VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages |
title_full | VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages |
title_fullStr | VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages |
title_full_unstemmed | VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages |
title_short | VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages |
title_sort | vh3-53/66-class rbd-specific human monoclonal antibody ib20 displays cross-neutralizing activity against emerging sars-cov-2 lineages |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224930/ https://www.ncbi.nlm.nih.gov/pubmed/35743680 http://dx.doi.org/10.3390/jpm12060895 |
work_keys_str_mv | AT kulemzinsergeyv vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages AT sergeevamariav vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages AT baranovkonstantino vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages AT gorchakovandreya vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages AT guselnikovsergeyv vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages AT belovezhetstatyanan vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages AT volkovaolgayu vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages AT najakshinalexanderm vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages AT chikaevnikolaia vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages AT danilenkodariam vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages AT taraninalexanderv vh35366classrbdspecifichumanmonoclonalantibodyib20displayscrossneutralizingactivityagainstemergingsarscov2lineages |